4.5 Interaction with other medicinal products and other forms of interaction 
 In plaque psoriasis studies, the safety of Taltz  in combination with other immunomodulatory agents or phototherapy has not been evaluated.  In population pharmacokinetic analyses , clearance of ixekizumab was not affected by concomitant administration of oral corticosteroids, NSAIDs, sulfasalazine,  or methotrexate.  
 Cytochrome P450 s ubstrates  
 Results from an  interaction study in patients with moderate -to-severe psoriasis determined that 
12 weeks of administration of ixekizumab with substances metaboli sed by CYP3A4 (i.e., midazolam), CYP2C9 (i.e., warfarin), CYP2C19 (i.e., omeprazole), CYP1A2 (i.e., caffeine) or CYP2D6 (i.e., dextromethorphan) does not have a clinically significant impact on the pharmacokinetics of these substances.  
 
